Rho（D）

Anti-D immune globulin is a drug that is suitable for use when an Rh-negative mother gives birth or aborts an Rh-positive fetus. The Rh-D antigen in the fetal red blood cells can enter the maternal blood and react with the mother's immune active cells, causing an atypical immune reaction. Anti-D human immunoglobulin can destroy the Rh-D antigen entering the maternal blood and inhibit the maternal blood from producing anti-Rh (D) antibodies, thereby preventing Rh atypical immune responses.

Indications

Used to prevent Rh immunity

Specifications

Injections

Dosage

Intramuscular injection

In most cases:

·The mother should receive an injection of RhoGAM between 26-28 weeks of pregnancy.

·If the baby is found to be Rh(D) positive at birth, the mother needs to receive a second dose of RhoGAM within 72 hours after delivery.

·If the baby is determined to be Rh(D) negative at birth, the mother does not need to receive additional doses of RhoGAM injections.

Adverse reactions

Injection site reactions, including swelling, induration, redness, mild pain, or warmth. Rash, body aches, or temporary increase in temperature.

Notes

1. Do not inject intravenously. In the case of postpartum use, this product is intended for use by the mother only and not for injection into the newborn.

2. There may be a risk of transmitting infectious agents because it is made from human plasma.

3. Use caution in patients with previous severe systemic allergic reactions to human immunoglobulin.

4. Contains small amounts of immunoglobulin A (IgA), with a potential risk of hypersensitivity reactions in IgA-deficient individuals.

5. Patients treated with Rh-incompatible blood transfusions should be monitored for signs and symptoms of hemolytic reaction through clinical and laboratory means.

Special groups

None